An Open Label Single Arm Phase 1b/2 Study with Pharmacokinetic Sampling to Evaluate LY2181308 in Patients with Advanced Hepatocellular Carcinoma

Update Il y a 4 ans
Reference: EUCTR2006-002893-23

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Main objective : Phase 1b: To determine the recommended dose for the Phase 2 portion of this trial for patients with advanced hepatocellular cancer (HCC) with no other standard curative or palliative therapeutic option. Phase 2: To estimate the time to progression (TTP) for patients with advanced HCC who have received LY2181308.


Inclusion criteria

  • Hepatocellular carcinoma (HCC)